State Street ETF — Lower Costs, Broader Reach in Healthcare
By John Nada·Jul 4, 2026·3 min read
State Street's ETF offers broad healthcare exposure at lower cost, while Invesco targets pharmaceuticals with higher expenses. Scale and liquidity tip the balance.
Two forces pull in opposite directions within healthcare ETFs: breadth versus focus. On one hand, the State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) casts a wide net over the entire healthcare sector. On the other, the Invesco Pharmaceuticals ETF (NYSEMKT:PJP) zeroes in tightly on 29 pharmaceutical titans.
State Street's offering stands out with its low-cost structure. According to Yahoo Finance, the ETF's expense ratio is a mere 0.08%, a crucial factor for cost-conscious investors. It's not just about the fees, though; XLV's diversified index covers a swath of large-cap stocks, spreading its investments across biotechnology, life sciences, and health technology. Its heavyweight holdings include Eli Lilly, Johnson & Johnson, and AbbVie.
The SPDR fund's broad market reach is further underscored by its inclusion of 59 securities, launched in 1998, which supports a diversified investment strategy across various healthcare sub-sectors. This breadth provides investors with exposure to a wide array of industries within the healthcare field, mitigating risk by not being overly reliant on any single segment.
Yet, Invesco's approach has its own allure. With a concentration on pharmaceutical firms, this ETF offers deeper exposure to drug manufacturing and research, its big names being Eli Lilly, Abbott Laboratories, and AbbVie. Despite having a higher expense ratio, some investors may find value in its targeted nature.
Bitcoin ETFs Face $2 Billion Outflow in Two Weeks — Retail Sells, Institutions Steady
Bitcoin ETFs see $2 billion outflow as retail investors panic.
Invesco's ETF, established in 2005, focuses specifically on 29 U.S. pharmaceutical companies involved in research, development, and distribution. The emphasis on pharmaceutical giants provides investors with a focused stake in companies that are critical to drug development and innovation.
The size difference between these funds is stark. XLV isn't just larger; it dwarfs PJP in assets under management, which influences liquidity and trading volumes. Yahoo Finance highlights that XLV's scale results in much higher average trading volume and tighter bid-ask spreads, factors that often sway investor choice. The liquidity provided by XLV's larger asset base is an attractive feature for investors who prioritize ease of trading and reduced transaction costs.
Income seekers may find XLV's payouts more enticing. It offers a dividend yield that's 0.70 percentage points higher than PJP, another dimension where the broader ETF edges out its niche counterpart. Specifically, the SPDR ETF has paid $2.53 per share over the trailing 12 months, translating to a 1.6% yield based on its recent share price. In contrast, Invesco's ETF has paid $1.06 per share over the same period, resulting in a 0.9% yield.
Performance and risk are critical in evaluating these funds. Beta, a measure of price volatility relative to the S&P 500, is an important factor for risk-averse investors. The SPDR fund's diversified approach typically results in a more stable beta, appealing to those seeking steady investment returns.
In the end, State Street's ETF delivers more in terms of cost efficiency and diverse exposure. It's a strategic choice for those looking to capture the full spectrum of the healthcare sector, while Invesco's focused approach will appeal to those wanting a concentrated bet on pharmaceuticals.